ThyroSeq® Data Presented at Professional Meetings

2020

Endocrine Society (ENDO)

• Nikiforova MN, Nikitski A, Tebbets J, Tolino L, Manroa P, Yip L, Nikiforov YE.Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations. JES. 4(Suppl 1): OR21–02.
• Figge JJ, Gooding WE, Burman KD, Mayson S, Scheri RP, Sipos JA, Sippel RS, Steward DL, Yang SP, Yip L, Nikiforov YE, Carty SE. Do Ultrasound Patterns and Clinical Parameters Modify the Probability of Thyroid Cancer Predicted by Molecular Testing in Thyroid Nodules With Indeterminate Cytology? JES. 4(Suppl 1): MON–LB79.
• Desai D, Lepe M, Kim CS, Kobaly K, Baloch ZW, Mandel SJ. Thyroseq V3 GC for Bethesda III and IV: An Institutional Experience. JES. 4(Suppl 1): MON-498.
• Chittimoju SB, Drake FT, Lee SL.NIFTP: A Painstaking Diagnosis Through the Pathologist’s Eyes. JES. 4(Suppl 1): SAT-461.
• Miller E, Anolik JR. Poorly Differentiated Thyroid Cancer Arising from a Hyperfunctioning Nodule Treated with I-131. JES. 4(Suppl 1): SUN-478.
• Dengler SL, Reid L, Klump W, Shersher D, Squillante C, Ferber A, Morgan FH. A Diagnosis of Thyroid Cancer Reveals a Triple Threat. JES. 4(Suppl 1): SUN-491.

2019

American Thyroid Association (ATA)

• Nikiforova MN, Lepe M, Tolino L, Wald A, Baloch Z, Nikiforov Y. Thyroid Cytology Smear Slides: An Untapped Resource for ThyroSeq Testing.Thyroid. 2019; 29(S1):A-195.

• Kaya C, Dorsaint P, Sboner A, Mercurio S, Wha Eng K, Nikiforova M, Elemento O. Limitations of Detecting Pathogenic Variants from RNA-Seq Expression Data in FNA and Tissue Samples. Thyroid. 2019; 29(S1):A-201.

• Morariu EM, McCoy K, Manroa P, Nikiforova M, Nikiforov Y. Clinicopathologic characteristics of thyroid nodules positive for THADA-IGF2BP3 fusion. Thyroid. 2019; 29(S1):A-80.

• Karslioglu French E, Carty SE, Nikiforova M, Nikiforov Y. Clinicopathological Features of Thyroid Nodules with EIF1AX Mutations. Thyroid. 2019; 29(S1):A-80.

• Doerfler WR, Morariu EM, Chiosea S, Landau M, Nikiforova M, Nikiforov Y, Yip L, Manroa P. Correlation of Molecular Results with Clinico-Pathologic Features in 50 Hurthle Cell Tumors.Thyroid. 2019; 29(S1):A-137.

• Hescot S, Ghuzlan A, Borget I, Sheikh‐Alard H, Tolino L, Dupuy C, Nikiforov Y, Schlumberger M, Nikiforova M, Leboulleux S. Prognosis factors of recurrence and survival in poorly differentiated thyroid carcinoma. Thyroid. 2019; 29(S1):A-132.

• Chen T, Rivera J, Gilfix BM, Sadeghi N, Richardson K, Hier MP, Forest V, Caglar D, Fishman D, Payne RJ. The Role of ThyroSeq v3 Sequencing Panel in the Surgical Management of Indeterminate Thyroid Nodules: A Retrospective Cohort Study in a Public Healthcare Setting. Thyroid. 2019; 29(S1):A-21.

• Al Halabi F. Thyroseq v3 Guides Management of Thyroid Nodules with Indeterminate Cytology. Thyroid. 2019; 29(S1):A-84.

• Kimura B, Nagelberg J, Choe C, Chi N. Thyromegaly and Langerhans Cell Histiocytosis. Thyroid. 2019; 29(S1):A-115.

American Association of Clinical Endocrinologists (AACE)

• Nikiforova M, Nikitski A, Panebianco F, Kaya C, Nikiforov Y. GLIS-Rearranged Hyalinizing Trabecular Tumors Detected in FNA Samples: Can Surgery Be avoided? AACE 28th Annual Scientific and Clinical Congress. 2019.

• Tolino L, Nikiforova M, Troncone G, Wald A, Baloch Z, Nikiforov Y. Performance of ThyroSeq v3 Genomic Classifier in Fixed Cytology Smears. AACE 28th Annual Scientific and Clinical Congress. 2019.

• Yip L, Dhupar R, Hodak S, Favazza L, Gulec S, Carty S, Nikiforov Y, Nikiforova M. Diagnostic and Therapeutic Utility of NTRK Fusions Detected by Thyroseq Test in Thyroid Nodules and Cancer. AACE 28th Annual Scientific and Clinical Congress. 2019.

2018

American Thyroid Association (ATA)

• Nikiforova M, Wald A, Tolino L, Santana-Santos L, Hoda R, Nikiforov Y. Diagnostic and Therapeutic Utility of Gene Fusion Detection by ThyroSeq v3 Genomic Classifier (GC). Thyroid. 2018; 28(S1): A-169.

• Livhits MJ, Zhu C, Du L, Leung AM, Rao J, Levin M, Douek ML, Beckett KR, Cheung DS, Gofnung Y, Yeh MW. Genomic Sequencing Classifier versus ThyroSeq v3 in the Management of Indeterminate Thyroid Nodules: A Randomized Clinical Trial. Thyroid. 2018; 28(S1):A-185 .

• Nicholson KJ , Roberts M , McCoy KL , Carty SE , Yip L. Molecular Testing of Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid. 2018; 28(S1):A-109.

• Nikiforov Y, Abraham D, Baloch Z, Bernet V, Carty S, Chu K, Hodak S, Hu S, Lackan D, Mandel S, Milas M, Nikiforova M, Paparsenos A, Patel K, Patel S, Rivera B, Yip L, Foulkes W. Prevalence and Outcome of Thyroid Nodules Carrying DICER1 Mutations in Adult Patients: Study of 6,732 Thyroid Nodules.Thyroid. 2018; 28(S1):A-198.

American Association of Clinical Endocrinologists (AACE)

• Nikiforov Y, Hodak S, Mandel S, Baloch Z, Kuriloff D, Yeh M, Livhits M, Lupo M, Hannoush A, Lee S, Shaha A, Parangi S, Patel S, Abraham D, Sacks W, Lindemann T, Mendoza Salazar A, Trask C, Gulec S, Sacks B, LeBeau S, Natale K, Nikiforova M, McIver B. Real World Experience with ThyroSeq v3 Genomic Classifier in Thyroid Nodules with Indeterminate Cytology: Results of Testing the First 3,783 Consecutive Samples.Endocr Pract. 2018 Apr; 24(1):316.

• Gorris M, Henderson B. Intrathyroidal Hemorrhagic Parathyroid Cyst Diagnosed by ThyroSeq v3 Molecular Testing. Endocr Pract. 2018 Apr; 24(1):160.